These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38493648)

  • 1. Prevalence and risk factors of MAFLD and its metabolic comorbidities in community-based adults in China: A cross-sectional study.
    He Y; Yao N; Tian F; Liu L; Lin X; Chen X; Duan H; Jiang Y; Yu G; Song C; Wang D; Ma Q; Liu L; Wan H; Shen J
    Diabetes Metab Syndr; 2024 Mar; 18(3):102973. PubMed ID: 38493648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease.
    Guo B; Guo Y; Nima Q; Feng Y; Wang Z; Lu R; Baimayangji ; Ma Y; Zhou J; Xu H; Chen L; Chen G; Li S; Tong H; Ding X; Zhao X;
    J Hepatol; 2022 Mar; 76(3):518-525. PubMed ID: 34883157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
    Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
    BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-specific prevalence and risk factors of metabolic-associated fatty liver disease among 75,570 individuals in eastern China.
    Chang M; Shao Z; Wei W; Shen P; Shen G
    Front Endocrinol (Lausanne); 2023; 14():1241169. PubMed ID: 37822594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
    Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
    Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
    Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
    Hu Q; Chen Y; Bao T; Huang Y
    Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
    Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
    Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis.
    Liu S; Wang J; Wu S; Niu J; Zheng R; Bie L; Xin Z; Wang S; Lin H; Zhao Z; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Bi Y; Li M; Xu Y
    Metabolism; 2021 Jul; 120():154779. PubMed ID: 33895182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study.
    Farrell AM; Magliano DJ; Shaw JE; Thompson AJ; Croagh C; Ryan MC; Howell J
    Sci Rep; 2022 Feb; 12(1):1956. PubMed ID: 35121749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and Risk Factors of Metabolic Associated Fatty Liver Disease in Xinxiang, China.
    Li H; Guo M; An Z; Meng J; Jiang J; Song J; Wu W
    Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32168920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China.
    Yuan Q; Wang H; Gao P; Chen W; Lv M; Bai S; Wu J
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China.
    Yi M; Chen RP; Yang R; Chen H
    Diabet Med; 2017 Apr; 34(4):505-513. PubMed ID: 27334577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAFLD and glomerular hyperfiltration in subjects with normoglycemia, prediabetes and type 2 diabetes: A cross-sectional population study.
    Abbate M; Parvanova A; López-González ÁA; Yañez AM; Bennasar-Veny M; Ramírez-Manent JI; Reseghetti E; Ruggenenti P
    Diabetes Metab Res Rev; 2024 May; 40(4):e3810. PubMed ID: 38757431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary composition and its association with metabolic dysfunction-associated fatty liver disease among Chinese adults: A cross-sectional study.
    Niu Z; Liu J; Peng H; Wu X; Zheng X; Yao S; Xu C
    Arab J Gastroenterol; 2024 May; 25(2):205-213. PubMed ID: 38378357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea.
    Kim M; Yoon EL; Cho S; Lee CM; Kang BK; Park H; Jun DW; Nah EH
    Liver Int; 2022 Jul; 42(7):1536-1544. PubMed ID: 35338555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations.
    Feng Z; Zhao F; Wang Z; Tang X; Xie Y; Qiu L
    BMC Gastroenterol; 2024 Mar; 24(1):111. PubMed ID: 38491346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study.
    Liu Q; Zhao G; Li Q; Wu W; Zhang Y; Bian H
    BMC Gastroenterol; 2022 Nov; 22(1):471. PubMed ID: 36402947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.